Cargando…
Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392166/ https://www.ncbi.nlm.nih.gov/pubmed/37534337 http://dx.doi.org/10.1177/20363613231193566 |
| _version_ | 1785082891769741312 |
|---|---|
| author | Riaz, Rumaisa Khan, Afsheen Siddiqui, Tasmiyah |
| author_facet | Riaz, Rumaisa Khan, Afsheen Siddiqui, Tasmiyah |
| author_sort | Riaz, Rumaisa |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10392166 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103921662023-08-02 Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma Riaz, Rumaisa Khan, Afsheen Siddiqui, Tasmiyah Rare Tumors Letter to the Editor SAGE Publications 2023-07-31 /pmc/articles/PMC10392166/ /pubmed/37534337 http://dx.doi.org/10.1177/20363613231193566 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Riaz, Rumaisa Khan, Afsheen Siddiqui, Tasmiyah Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma |
| title | Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma |
| title_full | Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma |
| title_fullStr | Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma |
| title_full_unstemmed | Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma |
| title_short | Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma |
| title_sort | epcoritamab-bysp (epkinly) – a phenomenal breakthrough in the treatment of diffuse large b-cell lymphoma |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392166/ https://www.ncbi.nlm.nih.gov/pubmed/37534337 http://dx.doi.org/10.1177/20363613231193566 |
| work_keys_str_mv | AT riazrumaisa epcoritamabbyspepkinlyaphenomenalbreakthroughinthetreatmentofdiffuselargebcelllymphoma AT khanafsheen epcoritamabbyspepkinlyaphenomenalbreakthroughinthetreatmentofdiffuselargebcelllymphoma AT siddiquitasmiyah epcoritamabbyspepkinlyaphenomenalbreakthroughinthetreatmentofdiffuselargebcelllymphoma |